79
Views
12
CrossRef citations to date
0
Altmetric
Original Research

The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia

, &
Pages 2581-2593 | Published online: 16 May 2017
 

Abstract

Purpose

Refractory pediatric leukemia remains one of the leading causes of death in children. Intensification of current chemotherapy regimens to improve the outcome in these children is often limited by the effects of drug resistance and cumulative toxicity. Hence, the search for newer agents and novel therapeutic approaches are urgently needed to formulate the next-generation early-phase clinical trials for these patients.

Materials and methods

A comprehensive library of antimicrobials, including eight HIV protease inhibitors (nelfinavir [NFV], saquinavir, indinavir, ritonavir, amprenavir, atazanavir, lopinavir, and darunavir), was tested against a panel of pediatric leukemia cells by in vitro growth inhibition studies. Detailed target modulation studies were carried out by Western blot analyses. In addition, drug synergy experiments with conventional and novel antitumor agents were completed to identify effective treatment regimens for future clinical trials.

Results

Several of the HIV protease inhibitors showed cytotoxicity at physiologically relevant concentrations (half-maximal inhibitory concentration values ranging from 1–24 µM). In particular, NFV was found to exhibit the most potent antileukemic properties across all cell lines tested. Mechanistic studies show that NFV leads to the induction of autophagy and apoptosis possibly through the induction of endoplasmic reticulum stress. Furthermore, interference with cell signaling pathways, including Akt and mTOR, was also noted. Finally, drug combination studies have identified agents with potential for synergy with NFV in its antileukemic activity. These include JQ1 (BET inhibitor), AT101 (Bcl-2 family inhibitor), and sunitinib (TK inhibitor).

Conclusion

Here, we show data demonstrating the potential of a previously unexplored group of drugs to address an unmet therapeutic need in pediatric oncology. The data presented provide preclinical supportive evidence and rationale for future studies of these agents for refractory leukemia in children.

Supplementary materials

Figure S1 Combination studies with known chemotherapy regimens in Molm13.

Notes: Drugs were plated in 96-well plates alone and in combination with the IC50 of NFV, determined from the corresponding cell line cytotoxicity screens. (A) Plated drugs at 1 µM final concentration; (B) drugs at 0.1 µM. The cells were then added to each (5,000 cells/well) and incubated for four days before being read by Alamar blue assay. The control (DMSO) and NFV alone are shown with patterned bars.

Abbreviations: DMSO, dimetthylsulfoxide; IC50, half-maximal inhibitory concentration; NFV, nelfinavir.

Figure S1 Combination studies with known chemotherapy regimens in Molm13.Notes: Drugs were plated in 96-well plates alone and in combination with the IC50 of NFV, determined from the corresponding cell line cytotoxicity screens. (A) Plated drugs at 1 µM final concentration; (B) drugs at 0.1 µM. The cells were then added to each (5,000 cells/well) and incubated for four days before being read by Alamar blue assay. The control (DMSO) and NFV alone are shown with patterned bars.Abbreviations: DMSO, dimetthylsulfoxide; IC50, half-maximal inhibitory concentration; NFV, nelfinavir.

Table S1 Summary of clinical trials involving NFV to date (as per the NCI Clinical Trials Database)

Acknowledgments

This study was supported in part by the POETIC Foundation, Alberta Children’s Hospital Foundation, and the Kids Cancer Care Foundation of Alberta (KCCFA).

Disclosure

The authors report no conflicts of interest in this work.